PREVIEW: Johnson & Johnson gains with investors eyeing tariffs ahead of earnings

Shares of Johnson & Johnson JNJ.N rise 1% to $153.42 on Mon ahead of its first quarter results due before the market open on Tues with investors focused on how the pharmaceutical giant is dealing with tariffs imposed by President Donald Trump

Trump announced a 90-day freeze on some of his new tariffs but left in place 10% tariffs on most U.S. imports

Analysts expect JNJ to report rev of ~$21.57 bln, flat from a year ago, and EPS of $2.59, down ~4.5% from a year ago

Among 26 analysts that cover JNJ, avg rating is "BUY" and median PT is $169.50, per LSEG data

JNJ's rev has exceeded expectations 7 times over the last 8 quarters, while EPS has met estimates every time

JNJ is up 6.4% YTD compared with the S&P 500 health index .SPXHC, which is up just ~6%